Latest C-Met Stories

GRAND RAPIDS, Mich., Feb. 6, 2012 /PRNewswire/ -- A recent discovery by Van Andel Research Institute (VARI) scientists enables the prediction of patient sensitivity to proposed drug therapies for glioblastoma - the most common and most aggressive malignant brain tumor in humans. The study, published in January in the Proceedings of the National Academy of Science, investigated glioblastoma models characterized by cell signaling activation and gene...

(Ivanhoe Newswire) -- Thousands of individuals are diagnosed with Glioblastoma mutiforme (GMB) each year and given little hope of survival. Sadly this is one of the most difficult forms of brain cancer to treat and the most common. Due to the aggressive nature of GMB there have been few successful therapies for the treatment of this form of brain cancer.  A team at the University of California in San Francisco lead by Joanna Philips, and Zena Werb has discovered a possible new therapeutic...

Interferon-stimulated gene 15 (ISG15), a ubiquitin like protein, is highly elevated in a variety of cancers including breast cancer. How the elevated ISG15 pathway contributes to tumorigenic phenotypes remains unclear and is the subject of a study published in the January 2012 issue of Experimental Biology and Medicine. Dr. Shyamal Desai and her co-investigators from the Louisiana State University School of Medicine in New Orleans, the University of Pennsylvania School of Medicine in...

SAN DIEGO, May 26, 2011 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. announced today that apricoxib (Capoxigem®, TG01), its novel COX-2 inhibitor in development for select cancer types, demonstrated reversal of the epithelial-mesenchymal transition (EMT) in xenograft models of several types of solid tumors. These data results were presented at the 2011 American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium and the 2011 American Association for Cancer Research...

REDWOOD CITY, Calif., April 28, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing. OMP-18R5 is a monoclonal antibody that binds selected receptors in the Wnt signaling pathway and is the first antibody to specifically block these targets to enter human studies. The...

REDWOOD CITY, Calif., April 21, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics targeting cancer stem cells, today announced it has expanded its collaboration with Bayer HealthCare. Bayer's U.S. affiliate will manufacture clinical supplies of a second Wnt inhibitor in the alliance. Bayer will manufacture the bulk drug substance at its Berkeley, California clinical manufacturing center to support Phase 1 clinical testing planned to commence in...

Protein is key to early embryonic development, but later promotes spread of cancerIn the early stages of human embryogenesis, a transcription factor called Twist1 plays a key regulatory role in how the embryo assumes form and function. Much later in life, however, researchers at the University of California, San Diego School of Medicine, say Twist1 can re-emerge, taking a darker and more deadly turn.In a paper published in the March 15, 2011 issue of Cancer Cell, UCSD scientists led by Jing...

REDWOOD CITY, Calif., Jan. 10, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, today announced that patient dosing has commenced in a Phase 1 clinical trial of OMP-59R5 in patients with advanced solid tumor cancers. OMP-59R5 is a monoclonal antibody that binds selected Notch receptors and is the first antibody to specifically block these targets to enter human studies. The Phase 1 clinical trial of OMP-59R5 is a...

REDWOOD CITY, Calif., Nov. 2, 2010 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program. All of the grant applications submitted by the company received an award. The funds will be used to continue development of each of five promising...

WALTHAM, Mass., Nov. 1, 2010 /PRNewswire/ -- X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells. The grant was awarded by the US Department of the Treasury and reviewed by scientists at the Department of Health and Human Services. This grant provides X-BODY with...